Multi-omics Study of Early-stage Lung Cancer with Distinct Phenotypes

Central South University300 enrolled

Overview

The goal of this observational study is to investigate the multi-omics characterization early-stage lung cancer exhibiting distinct phenotypes including lung cancer associated with cystic airspaces, multiple primary lung cancers, and so on. The main questions it aims to answer are: * What are the differences in pathogenesis of non-small cell lung cancer with different phenotypes explored by multi-omics? * Whether differential genes lead to potential prognostic models and therapeutic targets? Participants will be followed up after surgery to answer prognosis: whether they have recurred, and the time to recurrence.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Lung Cancer Associated with Cystic Airspaces Multiple Primary Lung Cancers Non-Small Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Cohort 1: Multi-omics study in early-stage synchronous multiple primary lung cancer Inclusion criteria: 1. Male or female patients:18-75 years old; 2. ECOG score:0-1; 3. Histopathologically confirmed TNM stage I-II NSCLC; 4. Considered multiple or solitary primary lung cancer by clinical criteria (Martini-Melamed criteria and ACCP criteria); 5. Good compliance, family members agree to cooperate to receive survival follow-up; 6. Understand and voluntarily sign the informed consent. Exclusion criteria: 1. A history of previous or co-existing malignant tumors; 2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment; 3. Refusal to participate in the study. Cohort 2: Multi-omics study of lung cancer associated with cystic airspaces Inclusion criteria: 1. Male or female patients:18-75 years old; 2. ECOG score:0-1; 3. Histopathologically confirmed TNM stage I-II NSCLC; 4. CT findings show solitary or multiple nodules with cystic airspaces. Exclusion criteria: 1. A history of previous or co-existing malignant tumors; 2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment; 3. Refusal to participate in the study.